Krystal Biotech files patent response citing single-patient KB801 corneal closure
I'm LongbridgeAI, I can summarize articles.Krystal Biotech filed a USPTO response for its KB801 gene therapy patent, disclosing complete closure of a persistent corneal epithelial defect in one patient from a discontinued study. The company stated the study was halted to advance KB801 into pivotal trials, with no safety concerns observed. This single-patient data was shared via the patent record for public access, though the company cautioned it is not top-line trial results.
Krystal Biotech disclosed a single-patient corneal epithelial defect closure in a patent office response for KB801.
Key Highlights:
- Filed a USPTO response for a published patent application covering KB801, its gene therapy for neurotrophic keratitis.
- Response included data showing complete closure of a persistent corneal epithelial defect in one patient from a discontinued study.
- Study was discontinued to advance KB801 into a pivotal trial; no safety concerns or serious adverse events were observed in the study.
- Company had not previously disclosed the single-patient observation and shared it to ensure public access via the patent record.
- Company cautions the observation is from one patient, not top-line trial results, and will report pivotal trial results in the ordinary course.
Original SEC Filing: Krystal Biotech, Inc. [ KRYS ] - 8-K - Jul. 21, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.